{"id":55737,"date":"2023-04-12T15:04:33","date_gmt":"2023-04-12T13:04:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bioskryb-genomics-unveils-new-research-findings-related-to-breast-cancer-tumor-evolution\/"},"modified":"2023-04-12T15:04:33","modified_gmt":"2023-04-12T13:04:33","slug":"bioskryb-genomics-unveils-new-research-findings-related-to-breast-cancer-tumor-evolution","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bioskryb-genomics-unveils-new-research-findings-related-to-breast-cancer-tumor-evolution\/","title":{"rendered":"BioSkryb Genomics Unveils New Research Findings Related to Breast Cancer Tumor Evolution"},"content":{"rendered":"
\n

\nBioSkryb will present new findings at AACR 2023 that challenge the status quo in the single-cell analysis market<\/i><\/p>\n

DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb Genomics<\/a>, a pioneer in comprehensive single-cell multiomic research solutions, today announced that it will share new, groundbreaking research related to single-cell analysis of breast cancer biopsies and the expansion of its ResolveDNA\u00ae<\/a> product line at the AACR 2023 Annual Meeting<\/a> in Orlando, Florida.<\/p>\n

<\/a><\/p>\n

\nBioSkryb initially developed ResolveDNA to provide whole genome or whole exome amplification of single cells with a high allelic balance, limited artifacts, and a view across the genome, which has not been achieved by any other solution. Recently, the company announced the expansion of the portfolio with the launch of its first multi-omic product, ResolveOME\u2122<\/a>, a first of its kind solution that provides whole genome and whole transcriptome analysis from the same single cell in a single workflow.<\/p>\n

\nAt AACR, BioSkryb will present compelling new data on the benefits of ResolveOME in understanding the evolution of breast cancer in a way that has not been seen before. The two poster presentations will review over a dozen ductal cell carcinoma biopsies, surveying the impact of multiomic analysis at the single-cell level in nearly 1000 cells, and demonstrating how it enables copy number, structural variation, fusion detection, allele-specific expression, and standard variant identification. In these studies, ResolveOME allowed for a deeper understanding of the cellular ecosystem, providing insights into tumor phenotypes, immune evasion, and drug resistance, which have the potential to greatly impact cancer drug discovery and development efforts.<\/p>\n

\nBioSkryb will also present the first data ever released on its high-throughput ResolveDNA that allows researchers to comprehensively analyze thousands of single-cell genomes per day. This discussion will display the newly developed high-throughput, automated process with a low volume reaction using the latest ResolveDNA 2.5-hour chemistry, delivering >99% precision and >80% sensitivity with low rates of chimeric DNA formulation. These results from the high-throughput solution will establish BioSkryb and ResolveDNA as the preferential methodology for sequencing and analyzing high volumes of genomes in the most accurate and most effective manner.<\/p>\n

\nIn addition to these presentations, BioSkryb will also highlight the release of the most recent version of its bioinformatics platform, BaseJumper\u2122<\/a>, which includes new multiomic analysis visualization tools and performance improvements enabling the workflows for large sample sets.<\/p>\n

\n\u201cThis research has the potential to transform our understanding of how breast cancer evolves and proliferates, potentially having a major effect on treatment and patient outcomes,\u201d said Suresh Pisharody, CEO, BioSkryb. \u201cWe are excited to share our latest, transformative findings that underscore the power of ResolveDNA and ResolveOME to enable greater insights into the mechanisms driving complex disease.\u201d<\/p>\n

\nIf you are interested in attending any of the sessions, please add them to your itinerary in the online AACR Meeting Planner:<\/p>\n